ARTICLE | Finance

Thelin's Last Breath

Pfizer withdraws Thelin due to liver tox; little impact on PAH competition

December 13, 2010 8:00 AM UTC

The market's reaction was muted on Friday when Pfizer Inc. (NYSE:PFE) withdrew pulmonary arterial hypertension drug Thelin sitaxentan after two cases of fatal liver injury were reported in a clinical trial. Liver toxicity is known to be a class effect associated with endothelin receptor antagonists.

The two biotechs that market endothelin receptor antagonists for PAH rose on the day: Actelion Ltd. (SIX:ATLN) gained CHF0.65 to CHF52.70 and Gilead Sciences Inc. (NASDAQ:GILD) added $0.62 to $37.61...